杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2017/02/15 | 2,377 | 2,394 | 2,361 | 2,361 | +48 | +2.1% | 185,100 |
2017/02/14 | 2,350 | 2,351 | 2,311 | 2,313 | -36 | -1.5% | 173,900 |
2017/02/13 | 2,365 | 2,365 | 2,336 | 2,349 | +5 | +0.2% | 151,000 |
2017/02/10 | 2,320 | 2,356 | 2,311 | 2,344 | +62 | +2.7% | 166,900 |
2017/02/09 | 2,320 | 2,345 | 2,258 | 2,282 | -44 | -1.9% | 221,600 |
2017/02/08 | 2,349 | 2,396 | 2,310 | 2,326 | +11 | +0.5% | 368,500 |
2017/02/07 | 2,220 | 2,335 | 2,220 | 2,315 | +96 | +4.3% | 463,700 |
2017/02/06 | 2,253 | 2,265 | 2,207 | 2,219 | -269 | -10.8% | 557,200 |
2017/02/03 | 2,453 | 2,500 | 2,441 | 2,488 | +15 | +0.6% | 133,800 |
2017/02/02 | 2,485 | 2,503 | 2,460 | 2,473 | ±0 | ±0% | 112,300 |
2017/02/01 | 2,433 | 2,480 | 2,427 | 2,473 | +7 | +0.3% | 192,100 |
2017/01/31 | 2,467 | 2,481 | 2,457 | 2,466 | -18 | -0.7% | 161,500 |
2017/01/30 | 2,495 | 2,510 | 2,469 | 2,484 | -6 | -0.2% | 157,600 |
2017/01/27 | 2,511 | 2,514 | 2,477 | 2,490 | -29 | -1.2% | 183,200 |
2017/01/26 | 2,510 | 2,528 | 2,502 | 2,519 | +20 | +0.8% | 109,100 |
2017/01/25 | 2,526 | 2,536 | 2,491 | 2,499 | -21 | -0.8% | 81,100 |
2017/01/24 | 2,510 | 2,533 | 2,500 | 2,520 | -7 | -0.3% | 84,200 |
2017/01/23 | 2,540 | 2,546 | 2,515 | 2,527 | -50 | -1.9% | 86,700 |
2017/01/20 | 2,538 | 2,583 | 2,525 | 2,577 | +26 | +1% | 132,500 |
2017/01/19 | 2,550 | 2,558 | 2,524 | 2,551 | +15 | +0.6% | 103,800 |
2017/01/18 | 2,556 | 2,556 | 2,512 | 2,536 | -18 | -0.7% | 98,900 |
2017/01/17 | 2,595 | 2,595 | 2,553 | 2,554 | -37 | -1.4% | 88,100 |
2017/01/16 | 2,601 | 2,626 | 2,571 | 2,591 | -34 | -1.3% | 134,300 |
2017/01/13 | 2,599 | 2,625 | 2,586 | 2,625 | +34 | +1.3% | 133,000 |
2017/01/12 | 2,630 | 2,630 | 2,554 | 2,591 | -64 | -2.4% | 161,600 |
2017/01/11 | 2,655 | 2,659 | 2,625 | 2,655 | +8 | +0.3% | 146,200 |
2017/01/10 | 2,684 | 2,700 | 2,632 | 2,647 | -27 | -1% | 204,200 |
2017/01/06 | 2,622 | 2,676 | 2,614 | 2,674 | +58 | +2.2% | 210,900 |
2017/01/05 | 2,604 | 2,627 | 2,588 | 2,616 | +33 | +1.3% | 212,300 |
2017/01/04 | 2,557 | 2,596 | 2,550 | 2,583 | +76 | +3% | 231,900 |
2016/12/30 | 2,480 | 2,513 | 2,471 | 2,507 | +37 | +1.5% | 148,400 |
2016/12/29 | 2,480 | 2,492 | 2,463 | 2,470 | +5 | +0.2% | 130,700 |
2016/12/28 | 2,470 | 2,473 | 2,458 | 2,465 | -2 | -0.1% | 61,500 |
2016/12/27 | 2,442 | 2,487 | 2,442 | 2,467 | +4 | +0.2% | 81,300 |
2016/12/26 | 2,439 | 2,470 | 2,425 | 2,463 | +24 | +1% | 126,400 |
2016/12/22 | 2,453 | 2,459 | 2,427 | 2,439 | -30 | -1.2% | 109,800 |
2016/12/21 | 2,489 | 2,498 | 2,468 | 2,469 | -19 | -0.8% | 197,000 |
2016/12/20 | 2,478 | 2,497 | 2,469 | 2,488 | +6 | +0.2% | 183,000 |
2016/12/19 | 2,476 | 2,487 | 2,458 | 2,482 | +19 | +0.8% | 133,700 |
2016/12/16 | 2,435 | 2,469 | 2,435 | 2,463 | +33 | +1.4% | 194,300 |
2016/12/15 | 2,423 | 2,459 | 2,415 | 2,430 | +9 | +0.4% | 159,500 |
2016/12/14 | 2,450 | 2,467 | 2,414 | 2,421 | -28 | -1.1% | 194,200 |
2016/12/13 | 2,390 | 2,451 | 2,378 | 2,449 | +71 | +3% | 277,900 |
2016/12/12 | 2,378 | 2,387 | 2,353 | 2,378 | +13 | +0.5% | 163,700 |
2016/12/09 | 2,305 | 2,370 | 2,305 | 2,365 | +10 | +0.4% | 269,800 |
2016/12/08 | 2,369 | 2,369 | 2,335 | 2,355 | -5 | -0.2% | 160,500 |
2016/12/07 | 2,397 | 2,398 | 2,347 | 2,360 | -27 | -1.1% | 157,800 |
2016/12/06 | 2,380 | 2,398 | 2,370 | 2,387 | +22 | +0.9% | 157,600 |
2016/12/05 | 2,370 | 2,392 | 2,346 | 2,365 | -6 | -0.3% | 172,500 |
2016/12/02 | 2,361 | 2,375 | 2,326 | 2,371 | -14 | -0.6% | 308,500 |
1901~
1950
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム